the First Affiliated Hospital of Guangzhou TCM University
Welcome,         Profile    Billing    Logout  
 15 Trials 
19 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Yong
CSPPT2-TT, NCT04974151: China Stroke Primary Prevention Trial 2 for Participants with Hypertension and MTHFR 677 TT Genotype

Recruiting
4
24000
RoW
Amlodipine besylate, Amlodipine, Amlodipine besylate And Folic Acid, Amlodipine Folic Acid, Anye, 5-methyltetrahydrofolate (5-MTHF), 5-MTHF, Amlodipine placebo, Amlodipine (dummy), Amlodipine folic acid placebo, Amlodipine folic acid (dummy), 5-MTHF Placebos, 5-MTHF (dummy)
Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, First Affiliated Hospital Bengbu Medical College, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD
Hypertension, MTHFR 677 TT Genotype
06/29
06/29
CSPPT2-CC/CT, NCT04974138: China Stroke Primary Prevention Trial 2 for Participants with H-type Hypertension and MTHFR 677 CC/CT Genotype

Recruiting
4
32000
RoW
Amlodipine besylate, Amlodipine, Amlodipine besylate and folic acid, Amlodipine folic acid, Anye, Amlodipine placebos, Amlodipine (dummy), Amlodipine-folic acid placebos, Amlodipine-folic acid (dummy)
Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, First Affiliated Hospital Bengbu Medical College, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD
Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
06/29
06/29
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Recruiting
3
642
RoW
HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos
Shanghai Henlius Biotech
Gastric Cancer
10/23
10/24
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

Recruiting
3
1041
RoW
YZJ-1139 20mg, YZJ-1139 40mg, Placebo
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Insomnia Disorder
12/24
12/24
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Recruiting
3
510
Europe, Canada, Japan, US, RoW
LY3650150, Placebo, Standard therapy for INCS
Eli Lilly and Company
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
10/26
02/27
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting
3
408
RoW
KN046, placebo
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Pancreatic Ductal Adenocarcinoma
04/24
08/24
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial

Hourglass Feb 2024 - Dec 2024 : Data from SUMMIT trial in participants with heart failure with preserved ejection fraction and obesity
Completed
3
731
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
07/24
07/24
ANCHOR-2, NCT05281523 / 2021-005055-36: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US (based on ANCHOR-2 trial) for chronic rhinosinusitis with nasal polyps
Completed
3
264
Europe, Japan, US, RoW
Depemokimab (GSK3511294), Placebo
GlaxoSmithKline
Nasal Polyps
07/24
08/24
NCT06155383: Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Recruiting
2
90
RoW
Capecitabine, oxaliplatin, Disitamab Vedotin, RC48, Toripalimab, JS001
RemeGen Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
01/25
12/27
NCT06821503: Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Not yet recruiting
1/2
72
RoW
LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound), Gemcitabine hydrochloride for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Pancreatic Cancer
12/27
12/28
NCT05839106: Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors

Recruiting
1/2
200
RoW
PM1032 injection, PM1032
Biotheus Inc.
Advanced Tumor
04/25
12/25
NCT05554666: A Study of ASKG315 in Patients With Advanced Solid Tumors.

Recruiting
1
56
RoW
ASKG315
AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Advanced Solid Tumors
12/23
10/24
NCT05429008: A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm

Recruiting
1
99
RoW
HMPL-A83 injection, HMPL-A83
Hutchmed
Advanced Tumors
06/25
09/25
CIBI363A103, NCT06468098: A Study of IBI363 in Subjects With Advanced Malignancies

Recruiting
1
556
RoW
IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC
Innovent Biologics (Suzhou) Co. Ltd.
Advanced Malignancies
06/25
12/26
SJ-0003, NCT03594422: A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Recruiting
1
100
RoW
HQP1351
Ascentage Pharma Group Inc., HealthQuest Pharma Inc.
Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult
12/24
12/26
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Terminated
1
20
RoW
ABM-1310
ABM Therapeutics Shanghai Company Limited
Advanced Solid Tumor, BRAF V600 Mutation
06/24
06/24
NCT05606848: To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal Cancer

Recruiting
N/A
350
RoW
Nutrition Emulsion (TPF-T), Foods for special medical purposes [FSMP] for patients with tumors
Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd
Gastrointestinal Cancer
03/25
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Yong
CSPPT2-TT, NCT04974151: China Stroke Primary Prevention Trial 2 for Participants with Hypertension and MTHFR 677 TT Genotype

Recruiting
4
24000
RoW
Amlodipine besylate, Amlodipine, Amlodipine besylate And Folic Acid, Amlodipine Folic Acid, Anye, 5-methyltetrahydrofolate (5-MTHF), 5-MTHF, Amlodipine placebo, Amlodipine (dummy), Amlodipine folic acid placebo, Amlodipine folic acid (dummy), 5-MTHF Placebos, 5-MTHF (dummy)
Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, First Affiliated Hospital Bengbu Medical College, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD
Hypertension, MTHFR 677 TT Genotype
06/29
06/29
CSPPT2-CC/CT, NCT04974138: China Stroke Primary Prevention Trial 2 for Participants with H-type Hypertension and MTHFR 677 CC/CT Genotype

Recruiting
4
32000
RoW
Amlodipine besylate, Amlodipine, Amlodipine besylate and folic acid, Amlodipine folic acid, Anye, Amlodipine placebos, Amlodipine (dummy), Amlodipine-folic acid placebos, Amlodipine-folic acid (dummy)
Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, First Affiliated Hospital Bengbu Medical College, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD
Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
06/29
06/29
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Recruiting
3
642
RoW
HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos
Shanghai Henlius Biotech
Gastric Cancer
10/23
10/24
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

Recruiting
3
1041
RoW
YZJ-1139 20mg, YZJ-1139 40mg, Placebo
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Insomnia Disorder
12/24
12/24
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Recruiting
3
510
Europe, Canada, Japan, US, RoW
LY3650150, Placebo, Standard therapy for INCS
Eli Lilly and Company
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
10/26
02/27
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting
3
408
RoW
KN046, placebo
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Pancreatic Ductal Adenocarcinoma
04/24
08/24
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial

Hourglass Feb 2024 - Dec 2024 : Data from SUMMIT trial in participants with heart failure with preserved ejection fraction and obesity
Completed
3
731
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
07/24
07/24
ANCHOR-2, NCT05281523 / 2021-005055-36: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US (based on ANCHOR-2 trial) for chronic rhinosinusitis with nasal polyps
Completed
3
264
Europe, Japan, US, RoW
Depemokimab (GSK3511294), Placebo
GlaxoSmithKline
Nasal Polyps
07/24
08/24
NCT06155383: Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Recruiting
2
90
RoW
Capecitabine, oxaliplatin, Disitamab Vedotin, RC48, Toripalimab, JS001
RemeGen Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
01/25
12/27
NCT06821503: Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Not yet recruiting
1/2
72
RoW
LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound), Gemcitabine hydrochloride for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Pancreatic Cancer
12/27
12/28
NCT05839106: Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors

Recruiting
1/2
200
RoW
PM1032 injection, PM1032
Biotheus Inc.
Advanced Tumor
04/25
12/25
NCT05554666: A Study of ASKG315 in Patients With Advanced Solid Tumors.

Recruiting
1
56
RoW
ASKG315
AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Advanced Solid Tumors
12/23
10/24
NCT05429008: A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm

Recruiting
1
99
RoW
HMPL-A83 injection, HMPL-A83
Hutchmed
Advanced Tumors
06/25
09/25
CIBI363A103, NCT06468098: A Study of IBI363 in Subjects With Advanced Malignancies

Recruiting
1
556
RoW
IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC
Innovent Biologics (Suzhou) Co. Ltd.
Advanced Malignancies
06/25
12/26
SJ-0003, NCT03594422: A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Recruiting
1
100
RoW
HQP1351
Ascentage Pharma Group Inc., HealthQuest Pharma Inc.
Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult
12/24
12/26
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Terminated
1
20
RoW
ABM-1310
ABM Therapeutics Shanghai Company Limited
Advanced Solid Tumor, BRAF V600 Mutation
06/24
06/24
NCT05606848: To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal Cancer

Recruiting
N/A
350
RoW
Nutrition Emulsion (TPF-T), Foods for special medical purposes [FSMP] for patients with tumors
Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd
Gastrointestinal Cancer
03/25
03/25

Download Options